Latest Biotech News

The Paul Drude Institute and Bizmuth MBE Ltd. unveiled a collaborative project integrating large language models and multimodal AI technologies to autonomously control molecular beam epitaxy (MBE)...

City of Hope developed HopeLLM, a generative AI platform leveraging extensive oncology data to streamline clinical workflows and enhance patient personalization. The platform automates new patient...

Revolution Medicines (Revmed) closed a landmark $2 billion flexible funding agreement with Royalty Pharma to support late-stage development and commercialization of its RAS(ON) multi-selective...

Nektar Therapeutics announced successful Phase 2b results for rezpegaldesleukin (rezpeg), an IL-2 pathway agonist, in moderate to severe atopic dermatitis. The drug hit primary and secondary...

Cidara Therapeutics reported positive mid-stage data for CD388, a drug-Fc conjugate antiviral providing season-long prophylaxis against influenza A and B viruses. Phase 2b results showed that a...

Researchers demonstrated that incorporating detailed knee alignment parameters into deep learning models significantly enhances the accuracy of predicting ground reaction forces during walking....

A team led by the University Medical Center Utrecht successfully applied mitochondrial base editing (mtBE) using a DddA-derived cytosine base editor (DdCBE) to precisely correct deleterious...

An international consortium including the Garvan Institute developed AAnet, an artificial neural network leveraging single-cell gene expression data to resolve the diverse cellular populations...

The FDA is investigating Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy following patient deaths linked to liver failure. This regulatory scrutiny highlights concerns over...

Revolution Medicines closed a flexible funding agreement with Royalty Pharma for up to $2 billion to accelerate late-stage development and commercialization of its RAS(ON) inhibitors, including...

Nektar Therapeutics reported positive Phase 2b results for rezpegaldesleukin in moderate to severe atopic dermatitis, achieving primary and secondary endpoints. The immunomodulatory biologic...

Vertex Pharma disclosed one-year data indicating durable blood glucose control with their stem cell-derived islet cell therapy (zimislecel) in Type 1 diabetes patients. Most participants achieved...

Pioneering AI methods are revolutionizing materials science, including semiconductor thin-film growth and composite material design. Collaborations between institutes are integrating large...

Researchers in the Netherlands successfully applied mitochondrial base editing using DdCBE technology to correct pathogenic mitochondrial DNA mutations in patient-derived models. This advancement...

Advanced AI tools have emerged to dissect intratumoral heterogeneity with precision, potentially transforming cancer treatment personalization. Meanwhile, CAR-T cell therapy advances confront...

New PET tracers targeting PD-L1 for head and neck cancer and glypican-3 for early hepatocellular carcinoma detection have shown enhanced specificity and imaging clarity. Concurrently, novel...

The FDA experiences a rapid turnover of senior leadership, including the administrative leave and departure of key executives within the Center for Biologics Evaluation and Research and Center for...

Physicians advocate for prioritizing legumes as key protein food sources in upcoming US dietary guidelines, underscoring their nutritional benefits. Studies reveal irrigation's dual impact on...

A multinational consortium led by the Garvan Institute of Medical Research has introduced AAnet, an advanced AI-driven framework designed to delineate cellular heterogeneity within tumors with...

Revolution Medicines has secured up to $2 billion from Royalty Pharma through a flexible funding agreement consisting of $1.25 billion in synthetic royalties and $750 million in corporate debt....